Dr. Nancy L. Bartlett
Claim this profileWashington University School of Medicine
Area of expertise
Lymphoma
Nancy L. Bartlett has run 6 trials for Lymphoma. Some of their research focus areas include:
Non-Hodgkin's Lymphoma
Nancy L. Bartlett has run 6 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Siteman Cancer Center At West County Hospital
Clinical Trials Nancy L. Bartlett is currently running
Thiotepa + Stem Cell Transplant
for Lymphoma
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk. Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma. The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration. This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.
Recruiting
1 award
Phase 2
3 criteria
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Recruiting
2 awards
Phase 3
More about Nancy L. Bartlett
Clinical Trial Related
7 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Nancy L. Bartlett has experience with
- Nivolumab
- Brentuximab Vedotin
- Rituximab
- Mosunetuzumab
- Dacarbazine
- Cyclophosphamide
Breakdown of trials Nancy L. Bartlett has run
Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nancy L. Bartlett specialize in?
Nancy L. Bartlett focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage III patients, or patients who are Stage IV.
Is Nancy L. Bartlett currently recruiting for clinical trials?
Yes, Nancy L. Bartlett is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Nancy L. Bartlett has studied deeply?
Yes, Nancy L. Bartlett has studied treatments such as Nivolumab, Brentuximab Vedotin, Rituximab.
What is the best way to schedule an appointment with Nancy L. Bartlett?
Apply for one of the trials that Nancy L. Bartlett is conducting.
What is the office address of Nancy L. Bartlett?
The office of Nancy L. Bartlett is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.